

Laura B Ramsey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/678047/publications.pdf>

Version: 2024-02-01

106
papers

3,618
citations

159585

30
h-index

144013

57
g-index

110
all docs

110
docs citations

110
times ranked

4888
citing authors

#	ARTICLE	IF	CITATIONS
1	<sc>PharmVar GeneFocus</sc>: <sc><i>SLCO1B1</i></sc>. Clinical Pharmacology and Therapeutics, 2023, 113, 782-793.	4.7	18
2	Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care. British Journal of Clinical Pharmacology, 2022, 88, 1418-1426.	2.4	21
3	Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians. Pediatric Research, 2022, 91, 529-538.	2.3	5
4	<i>CYP2D6*9</i> and <i>*41</i>: Does the Activity Value Assigned to these Alleles Need to be Reduced to more Accurately Predict Phenotype?. Clinical Pharmacology and Therapeutics, 2022, 111, 1208-1211.	4.7	1
5	Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy. Clinical and Translational Science, 2022, 15, 371-383.	3.1	13
6	Influence of CYP2D6 metabolizer status on ondansetron efficacy in pediatric patients undergoing hematopoietic stem cell transplantation: A case series. Clinical and Translational Science, 2022, 15, 610-618.	3.1	7
7	Editorial: Beyond Red Light, Green Light: Examining the Role of Pharmacogenomics in Evidence-Based Care in Child and Adolescent Psychiatry. Journal of the American Academy of Child and Adolescent Psychiatry, 2022, 61, 29-31.	0.5	3
8	The Clinical Pharmacogenetics Implementation Consortium Guideline for <i>SLCO1B1</i>, <i>ABCG2</i>, and <i>CYP2C9</i> genotypes and Statin-Associated Musculoskeletal Symptoms. Clinical Pharmacology and Therapeutics, 2022, 111, 1007-1021.	4.7	120
9	Selective Serotonin Reuptake Inhibitor Pharmacokinetics During Pregnancy: Clinical and Research Implications. Frontiers in Pharmacology, 2022, 13, 833217.	3.5	8
10	Pediatric Psychopharmacology for Depressive and Anxiety Disorders. Focus (American Psychiatric) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	2
11	Best-worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy. Implementation Science Communications, 2022, 3, 52.	2.2	4
12	A Double-Blind Randomized Trial to Investigate Mechanisms of Antidepressant-Related Dysfunctional Arousal in Depressed or Anxious Youth at Familial Risk for Bipolar Disorder. Journal of Personalized Medicine, 2022, 12, 1006.	2.5	2
13	Influence of albumin and methotrexate clearance on high-dose methotrexate-induced mucositis.. Journal of Clinical Oncology, 2022, 40, e15081-e15081.	1.6	0
14	Thoughtful Clinical Use of Pharmacogenetics in Child and Adolescent Psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 660-664.	0.5	26
15	CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 56-62.	1.3	9
16	Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems. Clinical Pharmacology and Therapeutics, 2021, 110, 179-188.	4.7	35
17	The need for a refined understanding of CYP2D6 in second-generation antipsychotic outcomes in children and adolescents. Pharmacogenomics, 2021, 22, 447-450.	1.3	1
18	Planning and Conducting a Pharmacogenetics Association Study. Clinical Pharmacology and Therapeutics, 2021, 110, 688-701.	4.7	4

#	ARTICLE	IF	CITATIONS
19	The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations. <i>Journal of Personalized Medicine</i> , 2021, 11, 615.	2.5	16
20	Toward pharmacogenetic SLCO1B1-guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model. <i>Clinical and Translational Science</i> , 2021, 14, 2267-2277.	3.1	3
21	Analysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 589-594.	4.7	9
22	<i>Letter to the Editor:</i> Sleep Disturbances in Selective Serotonin Reuptake Inhibitor-Treated Youth with Anxiety Disorders and Obsessive Compulsive Disorder—A Bayesian Hierarchical Modeling Meta-Analysis. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 387-388.	1.3	3
23	Systematic Review of Pharmacogenetic Factors That Influence High-Dose Methotrexate Pharmacokinetics in Pediatric Malignancies. <i>Cancers</i> , 2021, 13, 2837.	3.7	31
24	Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. <i>Genetics in Medicine</i> , 2021, 23, 2335-2341.	2.4	32
25	Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 559-562.	4.7	6
26	SLCO1B1 *15 allele is associated with methotrexate-induced nausea in pediatric patients with inflammatory bowel disease. <i>Clinical and Translational Science</i> , 2021, , .	3.1	5
27	Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, 60, 1309-1318.	0.5	14
28	Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 749692.	3.5	12
29	Characterizing Pharmacogenetic Testing Among Children's Hospitals. <i>Clinical and Translational Science</i> , 2021, 14, 692-701.	3.1	17
30	Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial. <i>Journal of Personalized Medicine</i> , 2021, 11, 1188.	2.5	6
31	Comparison of Severe Toxicities Following High Dose Methotrexate Administration By Demographics and over Time in Pediatric Patients with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 1970-1970.	1.4	0
32	Gene-Based Dose Optimization in Children. <i>Annual Review of Pharmacology and Toxicology</i> , 2020, 60, 311-331.	9.4	23
33	A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 50-52.	4.7	22
34	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28040.	1.5	38
35	PharmGKB summary: sertraline pathway, pharmacokinetics. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 26-33.	1.5	26
36	Cariprazine in Youth with Bipolar and Psychotic Disorders: A Retrospective Chart Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 267-272.	1.3	4

#	ARTICLE	IF	CITATIONS
37	CYP2C19 Metabolizer Status Does Not Influence the Safety or Efficacy of Pentamidine. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S94.	2.0	1
38	Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations. <i>Depression and Anxiety</i> , 2020, 37, 747-759.	4.1	7
39	MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 635-643.	4.7	32
40	The Influence of Pharmacodynamic Genes on Fluoxetine Response in Pediatric Anxiety and Depressive Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 276-277.	1.3	5
41	Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. <i>JAMA Network Open</i> , 2020, 3, e2029411.	5.9	34
42	Escitalopram in Adolescents With Generalized Anxiety Disorder. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	48
43	Implementation of Pharmacogenetics at Cincinnati Children's Hospital Medical Center: Lessons Learned Over 14 Years of Personalizing Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 49-52.	4.7	48
44	Pharmacogenetics of treating pediatric anxiety and depression. <i>Pharmacogenomics</i> , 2019, 20, 867-870.	1.3	17
45	Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27618.	1.5	24
46	Interpreting and Implementing Clinical Pharmacogenetic Tests: Perspectives From Service Providers. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 298-301.	4.7	6
47	Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models. <i>PLoS ONE</i> , 2019, 14, e0216328.	2.5	7
48	Pharmacogenetics of Sertraline Tolerability and Response in Pediatric Anxiety and Depressive Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 348-361.	1.3	32
49	Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. <i>Genetics in Medicine</i> , 2019, 21, 2255-2263.	2.4	53
50	Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders. <i>Frontiers in Pharmacology</i> , 2019, 10, 99.	3.5	70
51	CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 340-347.	1.3	35
52	Association of <i>SLCO1B1</i> *14 Allele with Poor Response to Methotrexate in Juvenile Idiopathic Arthritis Patients. <i>ACR Open Rheumatology</i> , 2019, 1, 58-62.	2.1	15
53	Racial Differences in Escitalopram/Citalopram-Related Weight Gain in Children and Adolescents: A Natural Language Processing-Based Electronic Medical Record Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 162-163.	1.3	5
54	<i>Sleeping Beauty</i> Screen Identifies <i>RREB1</i> and Other Genetic Drivers in Human B-cell Lymphoma. <i>Molecular Cancer Research</i> , 2019, 17, 567-582.	3.4	19

#	ARTICLE	IF	CITATIONS
55	Thyroid Function Screening in Children and Adolescents With Mood and Anxiety Disorders. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	6
56	Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review. <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2018, 48, 40-49.	1.7	49
57	A Single SNP in ADRB2 Halves the Opioid Requirement for Mucositis Pain in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S60-S61.	2.0	0
58	Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. <i>Oncologist</i> , 2018, 23, 52-61.	3.7	123
59	21.1 Overview of Pharmacogenetics and Implementation in a Large Child Psychiatry Unit. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, S300-S301.	0.5	0
60	21.3 Cyp2C19 Influence on Escitalopram Efficacy and Tolerability in Youth With Anxiety and Depression. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, S301.	0.5	2
61	Pharmacogenetic Testing and Antidepressants in Youth With Depressive and Anxiety Disorders. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, S300.	0.5	0
62	The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 2665-2665.	1.4	0
63	Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia. <i>Leukemia</i> , 2017, 31, 1325-1332.	7.2	25
64	Genome-wide Study Links <i>PNPLA3</i> Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 131-140.	4.7	50
65	Genetics of pleiotropic effects of dexamethasone. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 294-302.	1.5	17
66	Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. <i>Nature Immunology</i> , 2017, 18, 694-704.	14.5	67
67	Learning Health Systems as Facilitators of Precision Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 359-367.	4.7	22
68	6.38 Pharmacogenomics of Methylphenidate Side Effects in Children With Attention-Deficit/Hyperactivity Disorder (ADHD). <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, S289.	0.5	1
69	Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. <i>Pharmacotherapy</i> , 2017, 37, 1172-1190.	2.6	23
70	Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. <i>Blood</i> , 2016, 127, 558-564.	1.4	56
71	Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model. <i>PLoS ONE</i> , 2016, 11, e0151433.	2.5	40
72	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. <i>Blood</i> , 2015, 126, 69-75.	1.4	64

#	ARTICLE	IF	CITATIONS
73	Effect of Premedications in a Murine Model of Asparaginase Hypersensitivity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 541-551.	2.5	16
74	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. <i>Nature Genetics</i> , 2015, 47, 607-614.	21.4	126
75	Genome-Wide Association Study Identifies PNPLA3 I148M Variant Associated with Elevated Transaminase Levels after Induction Therapy in Pediatric ALL Patients. <i>Blood</i> , 2015, 126, 3714-3714.	1.4	2
76	Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2015, 10, e0135134.	2.5	13
77	Genetic Risk Factors for the Development of Osteonecrosis in Children Under Age 10 Treated for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 250-250.	1.4	0
78	A comprehensive evaluation of collapsing methods using simulated and real data: excellent annotation of functionality and large sample sizes required. <i>Frontiers in Genetics</i> , 2014, 5, 323.	2.3	14
79	Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 263-271.	1.5	9
80	Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. <i>European Journal of Cancer</i> , 2014, 50, 2685-2694.	2.8	67
81	The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 423-428.	4.7	379
82	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. <i>Blood</i> , 2014, 124, 1266-1276.	1.4	84
83	Abstract CT409: Dexamethasone (dex) and asparaginase increase triglycerides during acute lymphoblastic leukemia (ALL) therapy in children. , 2014, , .		0
84	A Murine Model of Asparaginase Allergy. <i>Blood</i> , 2014, 124, 2295-2295.	1.4	0
85	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. <i>Blood</i> , 2014, 124, 63-63.	1.4	6
86	Antileukemic Efficacy of Continuous Vs Discontinuous Dexamethasone in Murine Xenografts of Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3701-3701.	1.4	1
87	Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors. <i>Cell Reports</i> , 2013, 5, 1047-1059.	6.4	116
88	Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 126-130.	2.5	20
89	Genome-wide study of methotrexate clearance replicates SLCO1B1. <i>Blood</i> , 2013, 121, 898-904.	1.4	174
90	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 60-60.	1.4	1

#	ARTICLE	IF	CITATIONS
91	PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. <i>Human Molecular Genetics</i> , 2012, 21, 4793-4804.	2.9	56
92	Rare versus common variants in pharmacogenetics: <i>SLCO1B1</i> variation and methotrexate disposition. <i>Genome Research</i> , 2012, 22, 1-8.	5.5	232
93	Concordance of DMET Plus Genotyping Results With Those of Orthogonal Genotyping Methods. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 360-365.	4.7	51
94	The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for <i>SLCO1B1</i> and Simvastatin-Induced Myopathy. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 112-117.	4.7	294
95	IL-7 Functionally Segregates the Pro-B Cell Stage by Regulating Transcription of Recombination Mediators across Cell Cycle. <i>Journal of Immunology</i> , 2012, 188, 6084-6092.	0.8	37
96	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates <i>SLCO1B1</i> . <i>Blood</i> , 2012, 120, 2466-2466.	1.4	5
97	PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 530-530.	1.4	3
98	Host Thiopurine Methyltransferase Status Affects Mercaptopurine Antileukemic Effectiveness. <i>Blood</i> , 2012, 120, 3560-3560.	1.4	0
99	Substrain-specific differences in survival and osteonecrosis incidence in a mouse model. <i>Comparative Medicine</i> , 2012, 62, 466-71.	1.0	16
100	<i>Ebf1</i> or <i>Pax5</i> haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2011, 208, 1135-1149.	8.5	140
101	Functional Characterization of Liver Enhancers That Regulate Drug-Associated Transporters. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 571-578.	4.7	24
102	Tonic BCR signaling represses receptor editing via Raf- and calcium-dependent signaling pathways. <i>Immunology Letters</i> , 2011, 135, 74-77.	2.5	12
103	<i>Ebf1</i> or <i>Pax5</i> haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. <i>Journal of Cell Biology</i> , 2011, 193, i13-i13.	5.2	0
104	<i>SLCO1B1</i> Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics. <i>Blood</i> , 2011, 118, 571-571.	1.4	0
105	RAG-1 and ATM coordinate monoallelic recombination and nuclear positioning of immunoglobulin loci. <i>Nature Immunology</i> , 2009, 10, 655-664.	14.5	130
106	B Cell Receptor Basal Signaling Regulates Antigen-Induced Ig Light Chain Rearrangements. <i>Journal of Immunology</i> , 2008, 180, 4728-4741.	0.8	40